Maze Therapeutics (MAZE) EBIT Margin (2024 - 2026)
Maze Therapeutics (MAZE) reported EBIT Margin of -132.77% for Q1 2026.
Powered by 
Analysis
Maze Therapeutics (MAZE) EBIT Margin (2024 - 2026) Analysis & Trends
For FY2024, Maze Therapeutics posted EBIT Margin of 34.38%.
- The Q1 2026 figure ranks as the highest quarterly EBIT Margin since Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 37.40% |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -132.77% |
| Sep 30, 2024 | -969.16% |
| Jun 30, 2024 | 84.58% |
API Access
Maze Therapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=MAZE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "MAZE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=MAZE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();